The Chemours Company (NYSE:CC) has a beta value of 2.16 and has seen 0.61 million shares traded in the last trading session. The company, currently valued at $5.57B, closed the last trade at $33.37 per share which meant it lost -$0.33 on the day or -0.98% during that session. The CC stock price is -16.48% off its 52-week high price of $38.87 and 42.85% above the 52-week low of $19.07. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.9 million shares traded. The 3-month trading volume is 1.06 million shares.
The consensus among analysts is that The Chemours Company (CC) is an Overweight stock at the moment, with a recommendation rating of 2.20. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 6 out of 14 have rated it as a Hold, with 8 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is $0.94.
The Chemours Company (NYSE:CC) trade information
Sporting -0.98% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on Friday, 09/03/21 when the CC stock price touched $33.37 or saw a rise of 4.66%. Year-to-date, The Chemours Company shares have moved 34.61%, while the 5-day performance has seen it change -3.92%. Over the past 30 days, the shares of The Chemours Company (NYSE:CC) have changed 1.15%. Short interest in the company has seen 7.95 million shares shorted with days to cover at 6.57.
Wall Street analysts have a consensus price target for the stock at $41.17, which means that the shares’ value could jump 18.95% from current levels. The projected low price target is $35.00 while the price target rests at a high of $50.00. In that case, then, we find that the current price level is -49.84% off the targeted high while a plunge would see the stock gain -4.88% from current levels.
The Chemours Company (CC) estimates and forecasts
Figures show that The Chemours Company shares have outperformed across the wider relevant industry. The company’s shares have gained 26.64% over the past 6 months, with this year growth rate of 86.36%, compared to 23.10% for the industry. Other than that, the company has, however, increased its growth outlook for the 2021 fiscal year revenue. Growth estimates for the current quarter are 422.20% and 114.90% for the next quarter. Revenue growth from the last financial year stood is estimated to be 23.80%.
6 analysts offering their estimates for the company have set an average revenue estimate of $1.53 billion for the current quarter. 6 have an estimated revenue figure of $1.58 billion for the next quarter concluding in Sep 2021.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 36.00% over the past 5 years. Earnings growth for 2021 is a modest 517.30% while over the next 5 years, the company’s earnings are expected to increase by 27.50%.
The Chemours Company is expected to release its next earnings report between November 01 and November 05 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue. The forward dividend is 1.00 at a share yield of 3.00%. The company’s dividend yield has gone up over the past 12 months, with a 5 Year Average Dividend Yield of 3.10%.
The Chemours Company (NYSE:CC)’s Major holders
Insiders own 0.96% of the company shares, while shares held by institutions stand at 77.16% with a share float percentage of 77.91%. Investors are also buoyed by the number of investors in a company, with The Chemours Company having a total of 568 institutions that hold shares in the company. The top two institutional holders are FMR, LLC with over 19.5 million shares worth more than $544.11 million. As of Mar 30, 2021, FMR, LLC held 11.78% of shares outstanding.
The other major institutional holder is Vanguard Group, Inc. (The), with the holding of over 15.64 million shares as of Mar 30, 2021. The firm’s total holdings are worth over $436.39 million and represent 9.45% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and iShares Core S&P Midcap ETF. As of Mar 30, 2021, the former fund manager holds about 2.82% shares in the company for having 4.66 million shares of worth $130.11 million while later fund manager owns 4.53 million shares of worth $136.74 million as of Apr 29, 2021, which makes it owner of about 2.74% of company’s outstanding stock.